High-intensity focused ultrasound in the treatment of experimental liver cancer

R. Yang, C. R. Reilly, Frederick Rescorla, P. R. Faught, N. T. Sanghvi, F. J. Fry, T. D. Franklin, L. Lumeng, J. L. Grosfeld

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

High-intensity focused ultrasound (HIFU) was used to treat Morris rat hepatoma 3924A implanted in the liver. Treatment was administered with a lens-focused 4-MHz transducer that created a focused beam of 550 W/cm2 at peak intensity. One hundred twelve rats with liver tumors were divided into two groups of 56 each. Group 1 received HIFU therapy while group 2 (the control group) did not. All rats were killed immediately or 1, 3, 7, 14, 21, or 23 days after treatment. Eight rats in each group were killed at each interval for pathologic and biochemical studies. Significant inhibition of the tumor growth was seen in the HIFU-treated group, with tumor growth inhibition rates of 65.4% to 93.1% from the third to the 28th day after treatment. Ultrasound-treated tumors showed direct thermal cytotoxic necrosis and fibrosis. An additional 56 ACI rats with liver tumors were divided into four groups of 14 each. Group 1 received doxorubicin hydrochloride intraperitoneally and HIFU therapy; group 2, HIFU therapy; group 3, doxorubicin hydrochloride; and group 4 (the control group), neither HIFU nor doxorubicin hydrochloride. Significantly improved survival rates were noted in HIFU-treated animals (groups 1 and 2) compared with those of groups 3 and 4. These data suggest that HIFU may be a useful method for local treatment of hepatic tumors.

Original languageEnglish
Pages (from-to)1002-1010
Number of pages9
JournalArchives of Surgery
Volume126
Issue number8
StatePublished - 1991

Fingerprint

Liver Neoplasms
Doxorubicin
Neoplasms
Liver
Inbred ACI Rats
Experimental Liver Neoplasms
Control Groups
Group Psychotherapy
Growth
Transducers
Lenses
Fibrosis
Necrosis
Hot Temperature
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Yang, R., Reilly, C. R., Rescorla, F., Faught, P. R., Sanghvi, N. T., Fry, F. J., ... Grosfeld, J. L. (1991). High-intensity focused ultrasound in the treatment of experimental liver cancer. Archives of Surgery, 126(8), 1002-1010.

High-intensity focused ultrasound in the treatment of experimental liver cancer. / Yang, R.; Reilly, C. R.; Rescorla, Frederick; Faught, P. R.; Sanghvi, N. T.; Fry, F. J.; Franklin, T. D.; Lumeng, L.; Grosfeld, J. L.

In: Archives of Surgery, Vol. 126, No. 8, 1991, p. 1002-1010.

Research output: Contribution to journalArticle

Yang, R, Reilly, CR, Rescorla, F, Faught, PR, Sanghvi, NT, Fry, FJ, Franklin, TD, Lumeng, L & Grosfeld, JL 1991, 'High-intensity focused ultrasound in the treatment of experimental liver cancer', Archives of Surgery, vol. 126, no. 8, pp. 1002-1010.
Yang R, Reilly CR, Rescorla F, Faught PR, Sanghvi NT, Fry FJ et al. High-intensity focused ultrasound in the treatment of experimental liver cancer. Archives of Surgery. 1991;126(8):1002-1010.
Yang, R. ; Reilly, C. R. ; Rescorla, Frederick ; Faught, P. R. ; Sanghvi, N. T. ; Fry, F. J. ; Franklin, T. D. ; Lumeng, L. ; Grosfeld, J. L. / High-intensity focused ultrasound in the treatment of experimental liver cancer. In: Archives of Surgery. 1991 ; Vol. 126, No. 8. pp. 1002-1010.
@article{0ec9c9884a9d4baeba9a8fe97ae55c6f,
title = "High-intensity focused ultrasound in the treatment of experimental liver cancer",
abstract = "High-intensity focused ultrasound (HIFU) was used to treat Morris rat hepatoma 3924A implanted in the liver. Treatment was administered with a lens-focused 4-MHz transducer that created a focused beam of 550 W/cm2 at peak intensity. One hundred twelve rats with liver tumors were divided into two groups of 56 each. Group 1 received HIFU therapy while group 2 (the control group) did not. All rats were killed immediately or 1, 3, 7, 14, 21, or 23 days after treatment. Eight rats in each group were killed at each interval for pathologic and biochemical studies. Significant inhibition of the tumor growth was seen in the HIFU-treated group, with tumor growth inhibition rates of 65.4{\%} to 93.1{\%} from the third to the 28th day after treatment. Ultrasound-treated tumors showed direct thermal cytotoxic necrosis and fibrosis. An additional 56 ACI rats with liver tumors were divided into four groups of 14 each. Group 1 received doxorubicin hydrochloride intraperitoneally and HIFU therapy; group 2, HIFU therapy; group 3, doxorubicin hydrochloride; and group 4 (the control group), neither HIFU nor doxorubicin hydrochloride. Significantly improved survival rates were noted in HIFU-treated animals (groups 1 and 2) compared with those of groups 3 and 4. These data suggest that HIFU may be a useful method for local treatment of hepatic tumors.",
author = "R. Yang and Reilly, {C. R.} and Frederick Rescorla and Faught, {P. R.} and Sanghvi, {N. T.} and Fry, {F. J.} and Franklin, {T. D.} and L. Lumeng and Grosfeld, {J. L.}",
year = "1991",
language = "English",
volume = "126",
pages = "1002--1010",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - High-intensity focused ultrasound in the treatment of experimental liver cancer

AU - Yang, R.

AU - Reilly, C. R.

AU - Rescorla, Frederick

AU - Faught, P. R.

AU - Sanghvi, N. T.

AU - Fry, F. J.

AU - Franklin, T. D.

AU - Lumeng, L.

AU - Grosfeld, J. L.

PY - 1991

Y1 - 1991

N2 - High-intensity focused ultrasound (HIFU) was used to treat Morris rat hepatoma 3924A implanted in the liver. Treatment was administered with a lens-focused 4-MHz transducer that created a focused beam of 550 W/cm2 at peak intensity. One hundred twelve rats with liver tumors were divided into two groups of 56 each. Group 1 received HIFU therapy while group 2 (the control group) did not. All rats were killed immediately or 1, 3, 7, 14, 21, or 23 days after treatment. Eight rats in each group were killed at each interval for pathologic and biochemical studies. Significant inhibition of the tumor growth was seen in the HIFU-treated group, with tumor growth inhibition rates of 65.4% to 93.1% from the third to the 28th day after treatment. Ultrasound-treated tumors showed direct thermal cytotoxic necrosis and fibrosis. An additional 56 ACI rats with liver tumors were divided into four groups of 14 each. Group 1 received doxorubicin hydrochloride intraperitoneally and HIFU therapy; group 2, HIFU therapy; group 3, doxorubicin hydrochloride; and group 4 (the control group), neither HIFU nor doxorubicin hydrochloride. Significantly improved survival rates were noted in HIFU-treated animals (groups 1 and 2) compared with those of groups 3 and 4. These data suggest that HIFU may be a useful method for local treatment of hepatic tumors.

AB - High-intensity focused ultrasound (HIFU) was used to treat Morris rat hepatoma 3924A implanted in the liver. Treatment was administered with a lens-focused 4-MHz transducer that created a focused beam of 550 W/cm2 at peak intensity. One hundred twelve rats with liver tumors were divided into two groups of 56 each. Group 1 received HIFU therapy while group 2 (the control group) did not. All rats were killed immediately or 1, 3, 7, 14, 21, or 23 days after treatment. Eight rats in each group were killed at each interval for pathologic and biochemical studies. Significant inhibition of the tumor growth was seen in the HIFU-treated group, with tumor growth inhibition rates of 65.4% to 93.1% from the third to the 28th day after treatment. Ultrasound-treated tumors showed direct thermal cytotoxic necrosis and fibrosis. An additional 56 ACI rats with liver tumors were divided into four groups of 14 each. Group 1 received doxorubicin hydrochloride intraperitoneally and HIFU therapy; group 2, HIFU therapy; group 3, doxorubicin hydrochloride; and group 4 (the control group), neither HIFU nor doxorubicin hydrochloride. Significantly improved survival rates were noted in HIFU-treated animals (groups 1 and 2) compared with those of groups 3 and 4. These data suggest that HIFU may be a useful method for local treatment of hepatic tumors.

UR - http://www.scopus.com/inward/record.url?scp=0026407998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026407998&partnerID=8YFLogxK

M3 - Article

C2 - 1863205

AN - SCOPUS:0026407998

VL - 126

SP - 1002

EP - 1010

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 8

ER -